Verastem Oncology jumps after pricing $250M securities offering

BOSTON - Verastem Oncology, a biopharmaceutical company, announced the pricing of an underwritten public offering of 30.94 million shares of common stock at $8.00 per share. The transaction is expected to gross approximately $250 million before fees. Jefferies, Guggenheim Securities, and Cantor are serving as joint book-running managers, while B. Riley Securities acts as the lead manager.

The company aims to use the net proceeds to support clinical development of product candidates, including the VS-7375 program, and for general corporate purposes. The offering is conducted under a shelf registration statement effective since August 15, 2025. Verastem Oncology develops medicines for patients with cancers driven by the RAS/MAPK pathway, marketing AVMAPKI FAKZYNJA CO-PACK in the United States.